Carregant...
Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer
Human epidermal growth factor receptor (HER)2 over-expression is associated with a shortened disease-free interval and poor survival. Although the addition of trastuzumab to chemotherapy in the first-line setting has improved response rates, progression-free survival, and overall survival, response...
Guardat en:
| Autors principals: | , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2009
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2750101/ https://ncbi.nlm.nih.gov/pubmed/19664181 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/bcr2324 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|